PTGX Q3 2022 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$32M

Net Income

-$31M

EPS (Diluted)

$-0.61

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$282M

Total Liabilities

$39M

Stockholders' Equity

$244M

Cash & Equivalents

$153M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$10M	-100.0%
Gross Profit	$0	$10M	-100.0%
Operating Income	-$32M	-$34M	+4.8%
Net Income	-$31M	-$34M	+7.6%